New drug vs. brain stimulation: which stops suicidal thoughts faster?

NCT ID NCT06355180

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether a drug called esketamine works as well as electroconvulsive therapy (ECT) for quickly reducing suicidal thoughts in people with depression. 340 adults with major depression or bipolar disorder and active suicidal ideas took part. They received either esketamine infusions or ECT sessions over two weeks, and researchers tracked how many achieved remission of suicidal thoughts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Esketamine (a fast-acting antidepressant drug)
What this could lead to
If esketamine works as well as ECT, it could offer a less invasive, faster option to reduce suicidal thoughts in people with depression.
What could go wrong
This is a completed trial, but results are not yet published. Esketamine may not be as effective as ECT, and it can cause side effects like dissociation or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Anding Hospital

    Beijing, Beijing Municipality, 100088, China

  • Beijing Chaoyang District Third Hospital

    Beijing, China

  • Beijing Daxing District Xinkang Hospital

    Beijing, China

  • Inner Mongolia Autonomous Region Mental Health Center

    Hohhot, China

  • The Second People's Hospital of Dali Bai Autonomous Prefecture

    Dali, China

  • Wuhu Fourth People's Hospital

    Wuhu, Anhui, 241002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.